



(51) International Patent Classification:

C12P 21/08 (2006.01) A61K 38/19 (2006.01)
C07K 16/24 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2015/048260

(22) International Filing Date:

3 September 2015 (03.09.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/045,498 3 September 2014 (03.09.2014) US

(71) Applicants: **BOEHRINGER INGELHEIM INTERNATIONAL GMBH** [DE/DE]; Binger Strasse 173, 55216 Ingelheim Am Rhein (DE). **MACROGENICS, INC.** [US/US]; 9640 Medical Center Drive, Rockville, MD 20850 (US).

(72) Inventors: **BARRETT, Rachel, Rebecca**; Boehringer Ingelheim USA Corp., 900 Ridgebury Road, P.O.Box 368, Ridgefield, CT 06877-0368 (US). **JOHNSON, Leslie, S.**; 14411 Poplar Hill Road, Darnestown, MD 20874 (US).

SINGH, Sanjaya; Boehringer Ingelheim USA Corp., 900 Ridgebury Road, P.O.Box 368, Ridgefield, CT 06877-0368 (US). **LAST-BARNEY, Kathleen**; Boehringer Ingelheim USA Corp., 900 Ridgebury Road, P.O.Box 368, Ridgefield, CT 06877-0368 (US). **SHIH, Daw-Tsun**; Boehringer Ingelheim USA Corp., 900 Ridgebury Road, P.O.Box 368, Ridgefield, CT 06877-0368 (US). **GIBLIN, Patricia**; Boehringer Ingelheim USA Corp., 900 Ridgebury Road, P.O.Box 368, Ridgefield, CT 06877-0368 (US). **BRODEUR, Scott**; Boehringer Ingelheim USA Corp., 900 Ridgebury Road, P.O.Box 368, Ridgefield, CT 06877-0368 (US). **NAGARAJA, Nelamangala**; Boehringer Ingelheim USA Corp., 900 Ridgebury Road, P.O.Box 368, Ridgefield, CT 06877-0368 (US).

(74) Agent: **EL-HAYEK, Roque**; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,

[Continued on next page]

(54) Title: COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF




FIG. 1A

(57) Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.



KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))